Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Aligos Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 40
- +4 vs. Q3 2023
- Shares held
- 45.4M
- +19.6M (+76.2%) vs. Q3 2023
- Total value
- $30.1M
- +$10.9M (+56.6%) vs. Q3 2023
- New holders
- 9
- 8 more added
- Sold out
- 5
- 8 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 441 | $0 | 0.00% | −644,112−99.9% | Reduced |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% | 00.0% | Unchanged |
| ZRC Wealth Management, LLC | 100 | $75 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 293 | $195 | 0.00% | +98+50.3% | Added |
| JPMorgan Chase & Co | 677 | $450 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2,000 | $1.33K | 0.00% | 00.0% | Unchanged |
| Creative Planning | 10,050 | $6.67K | 0.00% | 00.0% | Unchanged |
| Zullo Investment Group, Inc. | 13,000 | $8.63K | 0.00% | +13,000 | New |
| Two Sigma Securities, LLC | 14,739 | $9.79K | 0.00% | +14,739 | New |
| CWM, LLC | 16,891 | $11.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 18,624 | $12.4K | 0.00% | −4,300−18.8% | Reduced |
| Tower Research Capital LLC (TRC) | 18,728 | $12.4K | 0.00% | +18,728 | New |
| HarbourVest Partners LLC | 18,783 | $12.5K | 0.00% | 00.0% | Unchanged |
| Choate Investment Advisors | 24,000 | $15.9K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 25,743 | $17.1K | 0.00% | +25,743 | New |
| Millennium Management LLC | 28,705 | $19.1K | 0.00% | −63,102−68.7% | Reduced |
| Charles Schwab Investment Management Inc | 31,383 | $20.8K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 53,968 | $35.8K | 0.00% | +14,617+37.1% | Added |
| Bridgeway Capital Management, LLC | 92,000 | $61.1K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 97,423 | $64.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 296,139 | $196.6K | 0.00% | −820−0.3% | Reduced |
| Geode Capital Management, LLC | 321,044 | $213.2K | 0.00% | +79,541+32.9% | Added |
| Renaissance Technologies LLC | 489,960 | $325.0K | 0.00% | +168,600+52.5% | Added |
| Acadian Asset Management LLC | 559,367 | $370.0K | 0.00% | −5,348−0.9% | Reduced |
| Silverarc Capital Management, LLC | 668,512 | $443.9K | 0.14% | +36,625+5.8% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $493.5K | 0.13% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,011,651 | $671.7K | 0.00% | +1,034+0.1% | Added |
| Bank of America Corp | 1,147,762 | $762.1K | 0.00% | −2,465−0.2% | Reduced |
| Newtyn Management, LLC | 1,255,000 | $833.3K | 0.16% | +335,000+36.4% | Added |
| Opaleye Management Inc. | 1,297,000 | $861.2K | 0.23% | +1,297,000 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,906,191 | $1.27M | 0.03% | −403,573−17.5% | Reduced |
| Baker Bros. Advisors LP | 2,076,400 | $1.38M | 0.02% | 00.0% | Unchanged |
| Tang Capital Management LLC | 2,189,847 | $1.45M | 0.13% | −1,139,201−34.2% | Reduced |
| Versant Venture Management, LLC | 2,320,381 | $1.54M | 0.40% | 00.0% | Unchanged |
| Altitude Crest Partners Inc. | 2,844,681 | $1.89M | 1.26% | +2,844,681 | New |
| Alyeska Investment Group, L.P. | 2,882,216 | $1.91M | 0.01% | +2,882,216 | New |
| Vivo Capital, LLC | 3,547,030 | $2.36M | 0.19% | 00.0% | Unchanged |
| Deep Track Capital, LP | 6,102,770 | $4.05M | 0.14% | +6,102,770 | New |
| EcoR1 Capital, LLC | 6,389,468 | $4.24M | 0.11% | +2,441,108+61.8% | Added |
| Armistice Capital, LLC | 6,833,875 | $4.54M | 0.12% | +6,833,875 | New |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −1,223,278−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,432−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −653−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −37−100.0% | Sold out |